Center for Molecular Medicine Cologne

Dr. med. Hans A Schlößer - Curriculum Vitae

Education and professional career

since 2017: Junior Consultant Department of General, Visceral and Cancer Surgery, University of Cologne
2012 - 2017: PostDoc at Cologne Interventional Immunology (PI Prof. M. von Bergwelt-Baildon)
2016: Board Certification Medical Tumor Therapy
2016: Board Certification Visceral Surgery
2011 - 2016: Residency Department of General, Visceral and Cancer Surgery, University of Cologne
2008 - 2011: Residency Department of Internal Medicine III (Hematology/Oncology), University of Bonn
2009: Dr. med. (MD) at the Department of Hematology and Oncology, University of Regensburg (chair Prof. R. Andreesen)
2008: Approbation in Medicine
2005 - 2008: MD student Laboratory for Tumor Immunology (PI Prof. A. Mackensen)
2000 - 2007: Medical School (University of Rostock, Rome, Regensburg, King’s College London)

Awards, distinctions and professional activities

since 2016: Member of the “Exzellenzakademie” of the German Society of Visceral Surgery
2013: Poster Award International Gastric Cancer Conference, Verona

Selected publications

Axel Lechner*,Hans A. Schlößer*,Sacha I. Rothschild*, Martin Thelen, Sabrina Reuter, Peter Zentis, Alexander Shimabukuro-Vornhagen, Sebastian Theurich, Kerstin Wennhold, Maria Garcia-Marquez, Lars Tharun, Jörg Isensee, Christian Hübbers, Michael von Bergwelt-Baildon*/Dirk Beutner*: Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint receptors in head and neck squamous cell carcinoma. Oncotarget (2017); 8(27):44418-44433 (*equal contribution).

Schlößer HA, Drebber U, Kloth M, Thelen M, Rothschild SI, Haase S, Garcia-Marquez M, Wennhold K, Berlth F, Urbanski A, Alakus H, Schauss A, Shimabukuro-Vornhagen A, Theurich S, Warnecke-Ebertz U, Stippel DL, Zippelius A, Büttner R, Hallek M, Hölscher AH, Zander T, Mönig SP and von Bergwelt-Baildon M: Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. Oncoimmunology (2015); 5(5):e1100789.

Schlößer HA, Thelen M, Dieplinger G, von Bergwelt-Baildon A, Garcia-Marquez MA, Reuter S, Shimabukuro-Vornhagen A, Wennhold K, Haustein N, Buchner D, Heiermann N, Kleinert R, Wahba R, Ditt V, Kurschat C, Cingöz T, Becker J, Stippel DL* and von Bergwelt-Baildon M*: Prospective analyses of circulating B-cell subsets in AB0-compatible and AB0-incompatible kidney transplant recipients. American Journal of Transplantation (2017); 17(2):542-550.

Schlößer HA, Drebber U, Urbanski A, Haase S, Baltin C, Berlth F, Neiß S, von Bergwelt-Baildon M, Fetzner UK, Warnecke-Eberz U, Bollschweiler E, Hölscher AH, Mönig SP, Alakus H: Glucose transporters 1, 3, 6, and 10 are expressed in gastric cancer and glucose transporter 3 is associated with UICC stage and survival. Gastric Cancer (2017); 20(1):83-91.

Shimabukuro-Vornhagen A, Schlößer HA*, Gryschok L, Malcher J, Wennhold K, Garcia-Marquez M, Herbold T, Neuhaus LS, Becker HJ, Fiedler A, Scherwitz P, Koslowsky T, Hake R, Stippel DL, Hölscher AH, Eidt S, Hallek M, Theurich S, von Bergwelt-Baildon MS: Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. Oncotarget (2014); 5(13):4651-64 (*equal contribution).

Wennhold K, Thelen M, Schlößer HA, Haustein N, Reuter S, Garcia-Marquez M, Lechner A, Kobold S, Rataj F, Utermöhlen O, Chakupurakal G, Theurich S, Hallek M, Abken H, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M: Using antigen-specific B cells to combine antibody and T cell based cancer immunotherapy. Cancer Immunology Research (2017); 5(9):730-743.

Theurich S, Schlaak M, Steguweit H, Heukamp LC, Wennhold K, Kurschat P, Rabenhorst A, Hartmann K, Schlößer HA, Shimabukuro-Vornhagen A, Holtick U, Hallek M, Stadler R, von Bergwelt-Baildon M: Targeting Tumor-Infiltrating B Cells in Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology (2016); 34(12).

Wennhold K*, Weber T *, Thelen M, Klein-Gonzalez N, Fiedler A, Garcia-Marquez M, Schlößer HA, Theurich S, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M:.CD40-activated B cells induce anti-tumor immunity in vivo. Oncotarget (2017); 8(17):27740-27753.